Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 2
2005 7
2006 8
2007 5
2008 10
2009 5
2010 11
2011 7
2012 8
2013 9
2014 14
2015 11
2016 12
2017 18
2018 11
2019 16
2020 18
2021 18
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L, Ocaña A, Pandiella A. Gandullo-Sánchez L, et al. Among authors: pandiella a. J Exp Clin Cancer Res. 2022 Oct 21;41(1):310. doi: 10.1186/s13046-022-02515-x. J Exp Clin Cancer Res. 2022. PMID: 36271429 Free PMC article. Review.
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Duro-Sánchez S, Nadal-Serrano M, Lalinde-Gutiérrez M, Arenas EJ, Bernadó Morales C, Morancho B, Escorihuela M, Pérez-Ramos S, Escrivá-de-Romaní S, Gandullo-Sánchez L, Pandiella A, Esteve-Codina A, Rodilla V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J. Duro-Sánchez S, et al. Among authors: pandiella a. Cancer Res. 2022 Dec 16;82(24):4670-4679. doi: 10.1158/0008-5472.CAN-22-0787. Cancer Res. 2022. PMID: 36222720 Free PMC article.
Resistance to Antibody-Drug Conjugates.
García-Alonso S, Ocaña A, Pandiella A. García-Alonso S, et al. Among authors: pandiella a. Cancer Res. 2018 May 1;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. Epub 2018 Apr 13. Cancer Res. 2018. PMID: 29653942 Review.
Refining Early Antitumoral Drug Development.
Ocaña A, García-Alonso S, Amir E, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29. Trends Pharmacol Sci. 2018. PMID: 30279003 Review.
Neuregulins and cancer.
Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Montero JC, et al. Among authors: pandiella a. Clin Cancer Res. 2008 Jun 1;14(11):3237-41. doi: 10.1158/1078-0432.CCR-07-5133. Clin Cancer Res. 2008. PMID: 18519747 Review.
Generation of Antibody-Drug Conjugate Resistant Models.
Gandullo-Sánchez L, Ocaña A, Pandiella A. Gandullo-Sánchez L, et al. Among authors: pandiella a. Cancers (Basel). 2021 Sep 15;13(18):4631. doi: 10.3390/cancers13184631. Cancers (Basel). 2021. PMID: 34572858 Free PMC article. Review.
Trastuzumab deruxtecan in breast cancer.
Martín M, Pandiella A, Vargas-Castrillón E, Díaz-Rodríguez E, Iglesias-Hernangómez T, Cano CM, Fernández-Cuesta I, Winkow E, Perelló MF. Martín M, et al. Among authors: pandiella a. Crit Rev Oncol Hematol. 2024 Apr 13:104355. doi: 10.1016/j.critrevonc.2024.104355. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 38621469 Free article. Review.
198 results